Matt O'Brien
Stock Analyst at Piper Sandler
(2.27)
# 2,768
Out of 5,055 analysts
195
Total ratings
44.17%
Success rate
-3.88%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TELA TELA Bio | Reiterates: Neutral | $2 → $1.25 | $1.00 | +25.09% | 7 | Nov 14, 2025 | |
| SI Shoulder Innovations | Reiterates: Overweight | $18 | $14.70 | +22.45% | 2 | Nov 12, 2025 | |
| CNMD CONMED | Maintains: Overweight | $68 → $55 | $42.04 | +30.83% | 14 | Nov 6, 2025 | |
| PRCT PROCEPT BioRobotics | Reiterates: Overweight | $55 → $50 | $29.69 | +68.41% | 5 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $75 | $58.06 | +29.18% | 13 | Oct 31, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $20 → $25 | $19.74 | +26.65% | 4 | Oct 31, 2025 | |
| TMDX TransMedics Group | Maintains: Overweight | $145 → $140 | $115.01 | +21.73% | 13 | Oct 30, 2025 | |
| BBNX Beta Bionics | Reiterates: Overweight | $26 → $32 | $27.18 | +17.73% | 2 | Oct 29, 2025 | |
| ITGR Integer Holdings | Maintains: Overweight | $155 → $82 | $69.49 | +18.00% | 3 | Oct 24, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $30 → $22 | $16.74 | +31.42% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $13.11 | +37.30% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $14 | $18.61 | -24.77% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $80 | $84.45 | -5.27% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $9.27 | +29.45% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $90.03 | +83.27% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $24.98 | +8.09% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $7.11 | -50.77% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $107.00 | +30.84% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $332.70 | -6.82% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $280.07 | +17.83% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $32.90 | +51.98% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $26.31 | -39.19% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $102.69 | +11.99% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $3.76 | +219.57% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $362.22 | +15.95% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $95.87 | -6.12% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $17.42 | +43.51% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.23 | +143.90% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.90 | +15.38% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $89.91 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $3.94 | +281.19% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $72.13 | +50.77% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $0.57 | +3,100.14% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $18.47 | +333.13% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.32 | +177.78% | 1 | Jun 24, 2020 |
TELA Bio
Nov 14, 2025
Reiterates: Neutral
Price Target: $2 → $1.25
Current: $1.00
Upside: +25.09%
Shoulder Innovations
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $14.70
Upside: +22.45%
CONMED
Nov 6, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $42.04
Upside: +30.83%
PROCEPT BioRobotics
Nov 5, 2025
Reiterates: Overweight
Price Target: $55 → $50
Current: $29.69
Upside: +68.41%
DexCom
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $58.06
Upside: +29.18%
Alphatec Holdings
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $19.74
Upside: +26.65%
TransMedics Group
Oct 30, 2025
Maintains: Overweight
Price Target: $145 → $140
Current: $115.01
Upside: +21.73%
Beta Bionics
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $27.18
Upside: +17.73%
Integer Holdings
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $69.49
Upside: +18.00%
OrthoPediatrics
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $16.74
Upside: +31.42%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $13.11
Upside: +37.30%
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $18.61
Upside: -24.77%
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $84.45
Upside: -5.27%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $9.27
Upside: +29.45%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $90.03
Upside: +83.27%
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $24.98
Upside: +8.09%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $7.11
Upside: -50.77%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $107.00
Upside: +30.84%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $332.70
Upside: -6.82%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $280.07
Upside: +17.83%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $32.90
Upside: +51.98%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $26.31
Upside: -39.19%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $102.69
Upside: +11.99%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $3.76
Upside: +219.57%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $362.22
Upside: +15.95%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $95.87
Upside: -6.12%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $17.42
Upside: +43.51%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.23
Upside: +143.90%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.90
Upside: +15.38%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $89.91
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $3.94
Upside: +281.19%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $72.13
Upside: +50.77%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $0.57
Upside: +3,100.14%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $18.47
Upside: +333.13%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.32
Upside: +177.78%